Airsupra is also the first ICS-containing product to win U.S. approval as a reliever treatment, rather than as a controller, for asthma. The inhalation aerosol is intended to treat or prevent bronchoconstriction and reduce the risk of asthma attacks in adult asthma patients, according to the FDA.
The product is made up of albuterol and budesonide, and the former is a popular asthma drug that is currently in shortage with “no presentations available,” according to the American Society of Health-System Pharmacist’s drug shortage website.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
